Resources Connection, Inc. (RECN) At $16.45 Forms Top; Shorts at Abiomed (ABMD) Lowered By 4.17%

Resources Connection, Inc. (NASDAQ:RECN) Logo

Abiomed Inc (NASDAQ:ABMD) had a decrease of 4.17% in short interest. ABMD’s SI was 1.20 million shares in May as released by FINRA. Its down 4.17% from 1.26 million shares previously. With 453,600 avg volume, 3 days are for Abiomed Inc (NASDAQ:ABMD)’s short sellers to cover ABMD’s short positions. The SI to Abiomed Inc’s float is 2.77%. The stock decreased 1.74% or $6.88 during the last trading session, reaching $387.4. About 1.22 million shares traded or 141.70% up from the average. ABIOMED, Inc. (NASDAQ:ABMD) has risen 190.17% since May 30, 2017 and is uptrending. It has outperformed by 177.60% the S&P500.

Resources Connection, Inc. (RECN) formed multiple top with $17.77 target or 8.00% above today’s $16.45 share price. Resources Connection, Inc. (RECN) has $518.43 million valuation. The stock increased 0.61% or $0.1 during the last trading session, reaching $16.45. About 120,658 shares traded. Resources Connection, Inc. (NASDAQ:RECN) has risen 27.73% since May 30, 2017 and is uptrending. It has outperformed by 15.16% the S&P500.

Since April 9, 2018, it had 0 insider buys, and 1 sale for $95,232 activity. On Monday, April 9 Wargotz Michael H sold $95,232 worth of Resources Connection, Inc. (NASDAQ:RECN) or 6,200 shares.

Investors sentiment increased to 1.74 in Q1 2018. Its up 0.88, from 0.86 in 2017Q4. It increased, as 4 investors sold Resources Connection, Inc. shares while 31 reduced holdings. 20 funds opened positions while 41 raised stakes. 24.45 million shares or 0.90% more from 24.23 million shares in 2017Q4 were reported. Wells Fargo And Mn has 46,417 shares for 0% of their portfolio. Barrow Hanley Mewhinney Strauss Limited Liability has invested 0.01% of its portfolio in Resources Connection, Inc. (NASDAQ:RECN). Tower Capital Lc (Trc) stated it has 3,723 shares. Us Bank De, Minnesota-based fund reported 208 shares. South Dakota Invest Council invested in 0.04% or 113,200 shares. Axa reported 190,722 shares or 0.01% of all its holdings. Public Employees Retirement Sys Of Ohio owns 36,216 shares or 0% of their US portfolio. Morgan Stanley reported 0% in Resources Connection, Inc. (NASDAQ:RECN). Arizona State Retirement System reported 46,500 shares stake. Sector Pension Investment Board has invested 0% in Resources Connection, Inc. (NASDAQ:RECN). 589 were accumulated by Bancshares Of Montreal Can. State Common Retirement Fund invested in 0% or 31,100 shares. Aperio Gru Limited Liability Co holds 0% or 12,430 shares in its portfolio. Marshwinds Advisory Co stated it has 17,550 shares or 0.14% of all its holdings. Prudential stated it has 120,980 shares or 0% of all its holdings.

Analysts await Resources Connection, Inc. (NASDAQ:RECN) to report earnings on July, 19. They expect $0.28 EPS, up 40.00% or $0.08 from last year’s $0.2 per share. RECN’s profit will be $8.82M for 14.69 P/E if the $0.28 EPS becomes a reality. After $0.18 actual EPS reported by Resources Connection, Inc. for the previous quarter, Wall Street now forecasts 55.56% EPS growth.

Among 4 analysts covering Resources Connection Inc. (NASDAQ:RECN), 0 have Buy rating, 3 Sell and 1 Hold. Therefore 0 are positive. Resources Connection Inc. has $1700 highest and $12 lowest target. $15’s average target is -8.81% below currents $16.45 stock price. Resources Connection Inc. had 10 analyst reports since August 18, 2016 according to SRatingsIntel. The firm earned “Hold” rating on Friday, August 25 by Robert W. Baird. Deutsche Bank maintained Resources Connection, Inc. (NASDAQ:RECN) on Friday, July 21 with “Sell” rating. The company was initiated on Thursday, August 18 by Deutsche Bank. On Friday, November 10 the stock rating was maintained by Robert W. Baird with “Hold”. The stock of Resources Connection, Inc. (NASDAQ:RECN) earned “Underweight” rating by JP Morgan on Thursday, January 4. Robert W. Baird maintained the shares of RECN in report on Wednesday, April 4 with “Hold” rating. As per Thursday, January 4, the company rating was downgraded by J.P. Morgan. On Thursday, October 6 the stock rating was maintained by Deutsche Bank with “Sell”. As per Thursday, October 6, the company rating was maintained by Robert W. Baird. The stock has “Hold” rating by Robert W. Baird on Wednesday, January 3.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company has market cap of $17.23 billion. It also provides continuum of care to heart failure patients. It has a 194.38 P/E ratio. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

More notable recent ABIOMED, Inc. (NASDAQ:ABMD) news were published by: Globenewswire.com which released: “Abiomed to Present at the Jefferies 2018 Healthcare Conference” on May 29, 2018, also Seekingalpha.com with their article: “PRAH +3% on MidCap 400 move; ABMD to S&P 500” published on May 25, 2018, Benzinga.com published: “Abiomed Earnings Outlook” on May 02, 2018. More interesting news about ABIOMED, Inc. (NASDAQ:ABMD) were released by: Benzinga.com and their article: “The Week Ahead In Biotech: ASCO Presentations In The Spotlight” published on May 26, 2018 as well as Seekingalpha.com‘s news article titled: “ABIOMED (ABMD) Q4 2018 Results – Earnings Call Transcript” with publication date: May 03, 2018.

Among 15 analysts covering Abiomed (NASDAQ:ABMD), 12 have Buy rating, 0 Sell and 3 Hold. Therefore 80% are positive. Abiomed has $370.0 highest and $80 lowest target. $259.73’s average target is -32.96% below currents $387.4 stock price. Abiomed had 36 analyst reports since August 4, 2015 according to SRatingsIntel. The firm has “Buy” rating by Guggenheim given on Friday, February 2. PiperJaffray upgraded ABIOMED, Inc. (NASDAQ:ABMD) on Thursday, April 6 to “Overweight” rating. The company was maintained on Thursday, August 3 by Jefferies. The stock of ABIOMED, Inc. (NASDAQ:ABMD) earned “Outperform” rating by Raymond James on Friday, October 30. On Tuesday, August 9 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by BTIG Research with “Hold” on Tuesday, August 4. Jefferies maintained ABIOMED, Inc. (NASDAQ:ABMD) rating on Thursday, December 21. Jefferies has “Buy” rating and $220.0 target. Jefferies maintained the shares of ABMD in report on Thursday, November 2 with “Buy” rating. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Equal-Weight” rating given on Friday, February 2 by Morgan Stanley. Northland Capital maintained it with “Market Perform” rating and $80 target in Wednesday, August 5 report.

Since February 20, 2018, it had 0 buys, and 5 selling transactions for $31.65 million activity. PUHY DOROTHY E sold $4.70 million worth of ABIOMED, Inc. (NASDAQ:ABMD) on Monday, May 7. $5.41 million worth of ABIOMED, Inc. (NASDAQ:ABMD) was sold by Greenfield Andrew J. BOLT WILLIAM J sold $7.93M worth of stock or 22,790 shares. The insider SUTTER MARTIN P sold $7.52M. 17,500 shares were sold by Howley Michael G, worth $6.09 million on Monday, May 7.

ABIOMED, Inc. (NASDAQ:ABMD) Institutional Positions Chart